Immune response suppression is crucial for viral invasion. The protein VP24 is pivotal in achieving this in Ebola, although interestingly the mechanism of immune suppression is different in the closely related Marburg virus. Here, we illustrate that a possible molecular basis for this difference emanates from two alpha helical structures ( 5 and 6) in VP24 involved in binding human α α karyopherin (KPNA) (PDBid:4U2X), wherein the Ebola and Marburg viruses have distinctly different charged properties in 5. 6 is absent in Marburg, and α α has a different hydrophobic moment in the Reston Ebola (REBOV) species, which is surprisingly non-pathogenic in humans. Based on the hypothesis that REBOV is not immunosuppressive, which is in turn is due to its inability to bind KPNA, we show by docking KPNA to the REBOV VP24 that the single amino acid substitution R140S is responsible for this difference between REBOV and Zaire Ebola strains. Such a scenario of getting a virulent REBOV through a single mutation is particularly worrisome, since the REBOV, once found only in monkeys, has been recently detected in pigs. We also reiterate the potential of using these helices as potential epitopes for generating protective antibodies against Ebola.
Introduction
Viruses from the family Filoviridae are negative-stranded RNA viruses having a filamentous shape 1 . The first member of this family (Marburg) was discovered in 1967 2 , while the Ebola virus was first discovered in 1976 3 . Public attention has been drawn to this rare, but deadly disease 4 ever since the current outbreak in West African countries threatened to rapidly deteriorate into a full-blown epidemic 5, 6 . Both viruses cause haemorrhagic fever by quickly suppressing innate antiviral immune responses 7 . However, quite surprisingly, the Reston Ebola (REBOV) strain, first identified in monkeys that were imported into Reston in the United States from the Philippines 8 , is non-pathogenic in humans 9, 10 . Previously, we have characterized α-helical (AH) structures in Ebola proteins using PAGAL 11 , and demonstrated that the AHs with characteristically unique feature values are involved in critical interactions with host proteins 12 . We showed that the AH from Ebola virus membrane fusion subunit GP2 13 , which is disrupted by a neutralizing antibody derived from a human survivor of the 1995 Kikwit outbreak 14 , has a very large hydrophobic moment compared to other AHs in Ebola proteins 12 . Similarly, another AH with the highest proportion of negatively charged residues is the binding site of the human karyopherin (KPNA) to the Zaire Ebola (ZEBOV) virus VP24 (ezVP24) protein 15 .
In spite of sharing a common ancestry 16 , Marburg and Ebola have different antigenicity of the virion glycoprotein 17 . Furthermore, the mechanism of immunosuppression is different in these viruses 18 . These differences are probably the reason for the reduced mortality observed in Marburg outbreaks. In Ebola, the crucial role of host immune system evasion is accomplished by two proteins: VP35 and VP24 19 . Ebola VP24 inhibits interferon (IFN) signaling by hindering the nuclear accumulation of tyrosine-phosphorylated STAT1 by binding KPNA 20, 21 . In contrast, the Marburg virus abrogates the host immune response by inhibiting IFN-induced tyrosine phosphorylation of STAT1 and STAT2 18 via a moonlighting function matrix protein, VP40 22 . Specifically, ezVP24 binds KPNA via two AHs (α5 and α6) 15 . In Marburg VP24 (mVP24), α5 has distinctively different properties (not easily identified by a sequence or structural alignment), while α6 is just a small turn 23 . This explains why mVP24 is not immunosuppressive.
We investigated these AHs in VP24 from the REBOV strain (erVP24). While α5 in erVP24 was similar to that in ezVP24, α6 in erVP24 had different properties caused by the presence of a serine in the place of arginine (S140R). We modeled the apo erVP24 (PDBid:4D9OA) using the ezVP24 in complex with KPNA as a template (PDBid:4U2X) by SWISS-MODEL 24 , and then docked KPNA to this structure using DOCLASP 25 . The docked structure helped visualize the ability of Arg140 in ezVP24 to make the correct electrostatic interaction with two glutamic acids, one residing on α5 in VP24, and the other in KPNA. The effect of single mutations in modulating virulence has been well established [26] [27] [28] . However, our methodology provides a more rational way of finding such critical residues. The possibility of a REBOV mutant gaining immunosuppressive capabilities is particularly disconcerting since the isolation of the REBOV strains from pigs [29] [30] [31] . We also highlight the possibility of using α5 and α6 from VP24 as epitopes for generating antibodies 32 or designing compounds and peptides to inhibit protein-protein interaction 33 .
Materials and methods
AHs in proteins were identified using DSSP 34 . These AHs were then analyzed using PAGAL 11 . Briefly, the Edmundson wheel is computed by considering a wheel with centre (0,0), radius 5, first residue coordinate (0,5) and advancing each subsequent residue by 100 degrees on the circle, as 3.6 turns of the AH makes one full circle. We compute the hydrophobic moment by connecting the center to the coordinate of the residue and giving it a magnitude obtained from the hydrophobic scale obtained from 35 . These vectors were then added to calculate the final hydrophobic moment. The color coding for the Edmundson wheel was as follows: all hydrophobic residues were colored red, while hydrophilic residues were colored in blue: dark blue for positively charged residues, medium blue for negatively charged residues and light blue for amides.
The protein structures used in the current work were all identified using the PDBid, and are available at www.rcsb.org. We used the SWISS-MODEL program to model the erVP24 (PDBid:4D9OA) structure using the ezVP24 (PDBid:4U2XA) in complex with KPNA as template. See 4D9OA4U2XA.pdb in Dataset 1 Note the residue numbering is not conserved by SWISS-MODEL. For example, Glu113 in PDBid:4D9OA corresponds to Glu97 in PDBid:4D9OA4U2XA. We used DOCLASP 25 to dock KPNA to the modelled structure of erVP24 (See Pymol script 'dockingKPNAtoRestonVP24.p1m' for human KPNA and 'RESTONVP24mouse.p1m' for mouse KNPA in Dataset 1). '4U2XA.4U2XD. maxdist.out.sort' in Dataset 1 lists the closest atoms of the residues of VP24 (PDBid:4U2XA) that make contact with human karyopherin (PDBid:4U2XD), sorted based on distances.
All protein structures were rendered by PyMol (http://www.pymol. org/). The sequence alignment was done using ClustalW
36
. The alignment images were generated using SeaView
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. Protein structures were superimposed using MUSTANG 38 .
Amendments from Version 1
In this version, based on the suggestion of a reviewer (Dr McIntosh), we have docked the modelled structure of VP24 from Reston Ebola (erVP24) virus to the structure of mouse KPNA (PDBid:1Y2AC) (there are no known models of KPNA from other non-human primates that are susceptible to Reston Ebola virus). However, inspite of sequence difference (50.3\% identity and 77.8\% similar) between human and mouse KPNA, the residues that interact with erVP24 is the same. However, Reston Ebola is known to be non-virulent in mice, although viral replication does occur (de Wit E, et al.) . Virulence in mice is caused only by a STAT1 knockout, corroborating the inability of erVP24 to suppress immune response, as hypothesized by us as a major cause for its non-pathogenicity.
The title of the article has been changed, Dataset 1 has been updated and a new Figure (Figure 5 ) has been added. . Therefore, we sought to investigate the differences in residues involved in binding KPNA in the ezVP24 and mVP24. ezVP24 binds KPNA via two AHs (α5 and α6), residues on loops and a Lys on a β-sheet (Table 1 ). In mVP24, α5 has different properties ( Figure 2a ,b and Table 2 ), while α6 is just a small turn (Figure 1c ). These differences in the properties of AHs involved in binding KPNA in eVP24 to those in mVP24 strongly indicates that mVP24 is not immunosuppressive, as is widely accepted 18 (or at least it does not use the same mechanism).
See referee reports

REVISED
Results and discussion
S140R substitution in α6 may explain why Ebola Reston strain is non-pathogenic in humans
The REBOV strain 'does not represent an immediate public health menace on the scale of the African Ebola virus' To better visualize and quantify this difference, we docked KPNA to erVP24. First, we modelled the apo erVP24 (PDBid:4D9OA) using the ezVP24 complexed with KPNA (PDBid:4U2X) using SWISS-MODEL 24 . Subsequently, KPNA was docked to this protein using DOCLASP 25 .
Figure 4 shows ezVP24 and erVP24 docked to KPNA. In ezVP2, KPNA binding is primarily facilitated by electrostatic attraction between the negatively charged Asp124 in α5 and Lys481 in KPNA (at 3.9 Å)
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, and a hydrogen bond between Arg140 (α6) and Glu475 of KPNA (among other hydrogen bonds, Table 3 ). Also, the ezVP24 itself is stabilized by an electrostatic bond between the negatively charged Glu113/OE1 (α5) and the positively charged Arg140/NH1 (α6) at 3.4 Å. Note, that this pair is at distance of 12.8 Å in the apo ezVP24 (PDBid:4M0QA). This 8 Å conformational change in these AHs emphasizes the role of plasiticity in binding KPNA. In contrast, in the erVP24, the distance between Glu113/OE1 and Ser140/OG changes from 14 Å in the apo enzyme to 6.2 Å in the docked model. Also, the Ser140/OG atom is not positively charged unlike Arg140/NH1. Further, the possibility of Ser140/OG making a hydrogen bond with Glu475 of KPNA is remote, since they are 6.7 Å apart. Thus, we conclude that the mutation R140S is likely to be one of the critical factors for the non-pathogenic nature of REBOV, since this mutation renders erVP24 incapable of binding KPNA. Other factors might include the different susceptibilities of the glycoproteins of ZEBOV and REBOV for furin cleavage 41 . 43 . Note, that erVP24 is able to directly bind STAT1 at levels similar to VP24 from other species 21 . However, apparently this binding is not sufficient to inhibit the IFN signalling pathway 43 . Thus, VP24 and its ability to bind KPNA plays a major role in the 'Reston-pathogenicity puzzle' 44 . Several putative sites, including a 'cluster of Reston-specific residues in VP24 is L136, R139 and S140', have been identified using deuterium exchange mass spectrometry methods 44 . Our computational method, with its associated caveats, identifies the S140 residue as being more critical than the other sites.
Role of intrinsically disordered stretches in VP24
It is interesting to note that the apo α5 (PDBid:4M0QA) is extended by two residues towards the N-terminal (Figure 2c , Glu113 and Pro114) in the ezVP24 complex with KPNA (PDBid:4U2XA). Notably, Pro and Glu are the two most disorder-promoting residues 45 . The peptide stretch preceding Glu113 in the Sudan Ebola VP24 (PDBid:3VNEA) is also disordered, and residues in that stretch are unassigned in the crystal structure ( Figure 1a ). Quite interestingly, the α6 (Figure 3a) is also extended by two residues (towards the C-terminal) in the ezVP24 complex ( Figure 3d ). As mentioned earlier, this stretch is not a helix in mVP24. In the apo Sudan Ebola VP24, α6 (Figure 3c ) is similar to the ezVP24 complex (Figure 3b) , and is already extended. This is probably due to the fact that Glu is replaced by Asp, which is not disordered-generating. Also, the hydrophobic moment of all three AHs have (almost) the same direction and magnitude (Figure 3a -c). These observations emphasizes the role of intrinsically disordered regions in viral functionality 46, 47 .
Conclusions
The ability of a single mutation to significantly alter the immunosuppressive properties of the Ebola proteins is well established 26, 27, 48 . . Structural studies provide an alternative, and possibly more rational, method to identify such mutations. For example, while double (and not single) mutations are required in VP35 to inhibit protein kinase R activation, it is difficult to rationalize this based on sequence data only 28 . In the current work, we build on previous work that characterized AH structures in Ebola proteins to rationalize the lack of immunosuppressive properties in the mVP24. ezVP24 binds to KPNA via two AHs (α5 and α5), loops and a residue on a β-sheet. We attribute the lack of immunosuppressive properties of mVP24 to its inability to bind KPNA, which emanates from different characteristics of mVP24 α5 compared to ezVP24 α5. Subsequently, we demonstrate that a single mutation in α6 in the erVP24 might endow it with immunosuppressive properties. We corroborate this conclusion by modelling the apo structure of the erVP24 based on the structure of ezVP24 in complex with KPNA using SWISS-MODEL 24 , and by docking KPNA to the modelled structure using DOCLASP 25 . The REBOV strain, first identified in monkeys and imported into the United States from the Philippines 8 , has never caused disease in humans 9,10 . However, the isolation of the REBOV strains from pigs in the Philippines 29, 30 , and recently in China
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, highlights the significance of finding preventive therapies in the probable scenario that a mutant REBOV for VP24 with immunosuppressive capabilities gets transferred to human handlers. Such a difference does not exist in the VP35 protein, where REBOV VP35 has been used as a model to show how they could silence and sequester double-stranded RNA, which is a key event in immunosuppression 49 . We also reiterate the potential of using these AHs from VP24 as epitopes 50,51 for generating antibodies 32,52,53 , or innovating drugs to inhibit proteinprotein interaction 33,54-58 . The presence of two intrinsically disordered residues proximal to these AHs in the apo structure that gain a AH structure upon binding should encourage antibody search to use both apo and complexed AHs. It is certainly worth investigating whether supplementing ZMapp, a cocktail of three antibodies that has shown reversion of advanced Ebola symptoms in non-human primates 59 , with more antibodies would prove more effective.
Data availability
F1000Research: Dataset 1. Version 2. Data used for SCALPEL search methodology to identify plant alpha helical -antimicrobial peptides in the PDB database. 10.5256/f1000research.5666.d40354 60 Author contributions SC wrote the computer programs. All authors analyzed the data, and contributed equally to the writing and subsequent refinement of the manuscript.
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Suggestions for revision:
The title seems too long. Single-point mutation in VP24 ---one of the key molecular mechanisms underlying the pathogenicity of filovirus.
The writing needs to be substantially improved. . Such a scenario of getting a virulent REBOV through a single mutation is particularly STAT1] worrisome, since the REBOV, once found only in monkeys, has been recently detected in pigs. We also reiterate the potential of using these helices as potential epitopes for generating protective antibodies against Ebola."
The abstract should be logically organized, starting from background information to methods, direct analyzed results, conclusion and finally the significance of present research.
In the introduction, some key information is missing which is indispensable for clear, accurate and logical understanding of the following analysis, related discussion and correlation between analysis and observed facts. "In Ebola, the crucial role of host immune system evasion is accomplished by two proteins: VP35 and VP24." ---What about Marburg? It's also dependent on VP35 and VP24 or just on VP24? because we are going to compare between Ebola and Marburg.
The main part of the article -computer modeling and analysis of VP24 and its interactions to other molecules -is reliable and sufficient. However, what makes the present analysis valuable is whether these analysis explain observed facts including pathogenicity between Marburg and Ebola virus, and among different Ebola species, and what about experimental findings by others? In other words, are there any experimental observations supporting present analysis?
In the Conclusion part of this article, the authors did not actually conclude their main analyzed results and corresponding significance. This "Conclusion" is actually a discussion.
About the discussion:
As both VP35 and VP24 contribute to "immune evasion" as described in "Introduction", how 7.
1.
2.
2.
As both VP35 and VP24 contribute to "immune evasion" as described in "Introduction", how could you get an accurate and reliable conclusion just based on the analysis of VP24? Change your angle of view.
All previous experimental observations and conclusions by other scientists about VP24 should be included in discussion, giving a comprehensive and impartial comparative analysis. However, some key studies are obviously missing in this part. For example:
The IFN system can protect immune-competent mice from lethal EBOV infection. Adaptation of ZEBOV to lethal infection of mice was associated with mutations in VP24 and NP ( ). However, both wild-type VP24 and VP24 of the mouse-adapted Ebihara That all EBOV species employ VP24 to subvert the host innate immune response by binding KPNA.
That a single point mutation R140S can explain a lack of pathogenesis by REBOV in humans through a lost capacity to bind KPNA. Neither of these assumptions have been experimentally verified by the authors or elsewhere. At a minimum, it seems these assumptions would need to be addressed in silico through analysis of the KPNA for a susceptible host to REBOV.
Minor concerns: Minor concerns:
Abstract "which is surprisingly non-pathogenic" ...to .."which is notably non-pathogenic in humans." "which is in turn is due to its inability to bind" ..to.."which is in turn due to its inability to bind ." Results and Discussion:
Dataset 1 title and legend appear to be mislabeled as "search methodology to identify plant alpha helica-antimicrobial peptides in the PDB dataset"...should this not be labeled as."to identify filovirus VP24 alpha helices"? Major Concerns: The added experiment of docking mouse KPNA to erVP24 is appreciated but does not address the important question of whether or not non-human primate KPNA has compensatory substitutions to restore the potential for binding Reston VP24. Following this line of thought, such compensatory substitutions would conversely not be expected to reduce binding with VP24 from other African species of EBOV. While the ability of single point mutations to abrogate protein-protein interactions is indeed well established, the ability of compensatory substitutions to restore intermolecular interactions is also well established. Would it not be more prudent to sequence KPNA from a non-human primate host susceptible to hemorrhagic disease caused by REBOV and test the hypothesis in silico? Understandably, access to non-human primate sequence is limiting making it difficult to address this concern. In light of the inability to validate these findings either experimentally or in silico with a susceptible host species for fatal disease with REBOV, I suggest that the observation of the R140S subsititution in REBOV and its forecast impact on pathogenicity, while intriguing, remains highly speculative.
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I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. . In this article, in addition to gross charge and structural differences in two alpha helices (a5 and a6) of VP24 between EBOV and Marburg viruses, possibly explaining the different mechanisms of INF response suppression, the authors hypothesis that a single substitution R140S in VP24 between the pathogenic Zaire ebolavirus (ZEBOV) and non-pathogenic Reston ebolavirus (REBOV) alters charged properties of the a5 alpha helix leading to a lack of binding to human KPNA by REBOV VP24. This substitution in REBOV VP24 is hypothesized to be responsible for the lack of REBOV pathogenesis in humans. The authors further express concern regarding the potential for a single amino acid substitution in REBOV, previously observed in domestic swine, to perhaps lead to a more pathogenic virus in the future.
Version 1
Article Content:
The study employs computational modeling of the primary VP24 amino acid sequences of different EBOV species and Marburg virus onto the previously resolved crystal structure of ZEBOV VP24 bound to KPNA5 (Xu , 2014) . The direct comparisons between potential binding sites of KPNA and VP24 et al. from different species of EBOV are intriguing but the study unfortunately lacks experimental verification either through binding or functional studies In addition there are concerns regarding the accuracy in vitro of theoretical modeling of primary VP24 sequences from various EBOV species to the known crystal structure of ZEBOV VP24 and KPNA5 peptides. Without experimental verification it is not possible to draw the conclusion that the R140S substitution present in REBOV affects binding to KPNA or that it is responsible for the absence of pathogenicity in humans. One approach not tried is modeling of a KPNA5 homolog from non-human primates as REBOV is known to still be pathogenic in non-human primates. In concept, it seems unlikely that a single mutation could be wholly responsible for the observed differences in pathogenicity between REBOV and other EBOV species. Various mechanisms not involving VP24 including EBOV glycoprotein and VP35-mediated mechanisms of immune suppression as well as a potential host genetic differences are likely to have critical influences on EBOV pathogenesis beyond the specific mechanism of VP24-mediated suppression of activated STAT1 nuclear localization and expression of INF triggered host antiviral mechanisms.
Of minor importance, invasion should be replaced with pathogenesis in the first sentence of the abstract and minor typographical errors should be corrected.
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